KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.

J Immunother Cancer · 2024-Oct-24 · PMID 39455094

Panel B质量警告待 EXE 对齐验证

Progression-free survival

Figure 3. Kaplan-Meier curves of the BIRC-assessed efficacy outcomes for GCB patients in the Hi-CHOP and R-CHOP groups (FAS). ( A ) Duration of response, ( B ) progression-free survival, ( C ) events-free survival and ( D ) overall survival note. The cut-off date for the analysis was August 31, 2022, with a median follow-up period of 29.6 months. BIRC, blinded independent review committee; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; FAS, full analysis set; GCB, germinal center B‐cell‐like; Hi-CHOP, zuberitamab plus CHOP; NE, not evaluable; R-CHOP, rituximab plus CHOP.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.50
质量通过否
预期曲线2
实际曲线1
X 范围0 – 39
Y 范围0 – 1.12

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

匹配 20 行
Curve序号X (norm)Y (norm)X (real)Y (real)X (pixel)Y (pixel)
110.00001.00000.00000.9764370
120.13731.00005.35520.9764830
130.14031.00005.47160.9764840
140.14331.00005.58810.9764850
150.14631.00005.70450.9764860
160.14931.00005.82090.9764870
170.15221.00005.93730.9764880
180.15521.00006.05370.9764890
190.15821.00006.17010.9764900
1100.16121.00006.28660.9764910
1110.16421.00006.40300.9764920
1120.16721.00006.51940.9764930
1130.17011.00006.63580.9764940
1140.17311.00006.75220.9764950
1150.17611.00006.86870.9764960
1160.17911.00006.98510.9764970
1170.18210.98917.10150.9658982
1180.18510.98917.21790.9658992
1190.18810.98917.33430.96581002
1200.19100.98917.45070.96581012
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T18:44:02+00:00